OPKO Health, Inc. (0KCS.L)
USD 1.41
(3.82%)
USD 1.41
(3.82%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 318.12 Million USD | -19.47% |
| 2022 | 288.2 Million USD | -50.44% |
| 2021 | 581.5 Million USD | 7.49% |
| 2020 | 541 Million USD | 64.24% |
| 2019 | 329.4 Million USD | -14.6% |
| 2018 | 385.7 Million USD | 11.51% |
| 2017 | 345.87 Million USD | -43.32% |
| 2016 | 610.2 Million USD | 719.49% |
| 2015 | -98.5 Million USD | 32.44% |
| 2014 | -145.8 Million USD | -405.85% |
| 2013 | 47.67 Million USD | 148.72% |
| 2012 | 19.16 Million USD | 78.52% |
| 2011 | 10.73 Million USD | -28.42% |
| 2010 | 14.99 Million USD | 318.97% |
| 2009 | 3.58 Million USD | 306.36% |
| 2008 | 881 Thousand USD | 2158.97% |
| 2007 | 39 Thousand USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 13 Thousand USD | -97.69% |
| 2002 | 562 Thousand USD | -57.84% |
| 2001 | 1.33 Million USD | 15.41% |
| 2000 | 1.15 Million USD | -26.67% |
| 1999 | 1.57 Million USD | 21.15% |
| 1998 | 1.3 Million USD | 550.0% |
| 1997 | 200 Thousand USD | 0.0% |
| 1996 | 200 Thousand USD | 150.0% |
| 1995 | -400 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 20.63 Million USD | -11.07% |
| 2024 Q2 | 31.23 Million USD | 51.38% |
| 2023 Q1 | 99.3 Million USD | 77.32% |
| 2023 Q2 | 126.47 Million USD | 27.37% |
| 2023 Q3 | 47.7 Million USD | -62.29% |
| 2023 FY | 232.09 Million USD | -19.47% |
| 2023 Q4 | 23.2 Million USD | -51.36% |
| 2022 Q2 | 115.58 Million USD | 35.43% |
| 2022 Q1 | 85.34 Million USD | -21.34% |
| 2022 FY | 288.2 Million USD | -50.44% |
| 2022 Q3 | 31.29 Million USD | -72.92% |
| 2022 Q4 | 56 Million USD | 78.92% |
| 2021 FY | 581.5 Million USD | 7.49% |
| 2021 Q1 | 181.65 Million USD | 3.27% |
| 2021 Q4 | 108.5 Million USD | -23.51% |
| 2021 Q3 | 141.85 Million USD | -5.11% |
| 2021 Q2 | 149.5 Million USD | -17.7% |
| 2020 Q4 | 175.9 Million USD | 13.27% |
| 2020 Q1 | 71.2 Million USD | -13.16% |
| 2020 Q3 | 155.29 Million USD | 12.08% |
| 2020 FY | 541 Million USD | 64.24% |
| 2020 Q2 | 138.55 Million USD | 94.58% |
| 2019 Q4 | 82 Million USD | -5.59% |
| 2019 Q1 | 78.5 Million USD | 8.58% |
| 2019 Q2 | 82.14 Million USD | 4.64% |
| 2019 Q3 | 86.85 Million USD | 5.73% |
| 2019 FY | 329.4 Million USD | -14.6% |
| 2018 Q3 | 98.85 Million USD | -13.0% |
| 2018 Q4 | 72.3 Million USD | -26.87% |
| 2018 Q1 | 100.8 Million USD | 171.7% |
| 2018 FY | 385.7 Million USD | 11.51% |
| 2018 Q2 | 113.62 Million USD | 12.72% |
| 2017 Q4 | 37.1 Million USD | -66.93% |
| 2017 Q3 | 112.18 Million USD | -28.46% |
| 2017 Q1 | 141.3 Million USD | 21.6% |
| 2017 Q2 | 156.8 Million USD | 10.97% |
| 2017 FY | 345.87 Million USD | -43.32% |
| 2016 FY | 610.2 Million USD | 719.49% |
| 2016 Q4 | 116.2 Million USD | -20.84% |
| 2016 Q3 | 146.8 Million USD | -27.92% |
| 2016 Q2 | 203.66 Million USD | 41.92% |
| 2016 Q1 | 143.5 Million USD | 1916.47% |
| 2015 Q4 | -7.9 Million USD | -110.44% |
| 2015 Q1 | 19.76 Million USD | 160.81% |
| 2015 Q2 | 27.99 Million USD | 41.65% |
| 2015 Q3 | 75.7 Million USD | 170.43% |
| 2015 FY | -98.5 Million USD | 32.44% |
| 2014 Q4 | -32.5 Million USD | -475.59% |
| 2014 Q2 | 10.98 Million USD | 11.1% |
| 2014 FY | -145.8 Million USD | -405.85% |
| 2014 Q1 | 9.88 Million USD | 14.33% |
| 2014 Q3 | 8.65 Million USD | -21.19% |
| 2013 Q2 | 10.71 Million USD | -45.37% |
| 2013 FY | 47.67 Million USD | 148.72% |
| 2013 Q4 | 8.64 Million USD | -0.52% |
| 2013 Q3 | 8.68 Million USD | -18.93% |
| 2013 Q1 | 19.61 Million USD | 164.73% |
| 2012 Q3 | 4.3 Million USD | 17.8% |
| 2012 Q2 | 3.65 Million USD | -3.51% |
| 2012 Q4 | 7.41 Million USD | 72.03% |
| 2012 Q1 | 3.79 Million USD | 131.66% |
| 2012 FY | 19.16 Million USD | 78.52% |
| 2011 Q3 | 2.79 Million USD | -29.03% |
| 2011 FY | 10.73 Million USD | -28.42% |
| 2011 Q4 | 1.63 Million USD | -41.36% |
| 2011 Q2 | 3.93 Million USD | 29.95% |
| 2011 Q1 | 3.02 Million USD | -66.52% |
| 2010 FY | 14.99 Million USD | 318.97% |
| 2010 Q2 | 2.6 Million USD | 8.81% |
| 2010 Q4 | 9.03 Million USD | 285.49% |
| 2010 Q1 | 2.39 Million USD | 32.19% |
| 2010 Q3 | 2.34 Million USD | -10.02% |
| 2009 Q2 | 583 Thousand USD | -21.22% |
| 2009 Q1 | 740 Thousand USD | 63.72% |
| 2009 FY | 3.58 Million USD | 306.36% |
| 2009 Q4 | 1.81 Million USD | 306.05% |
| 2009 Q3 | 446 Thousand USD | -23.5% |
| 2008 Q4 | 452 Thousand USD | -58.19% |
| 2008 FY | 881 Thousand USD | 2158.97% |
| 2008 Q1 | -506 Thousand USD | -1397.44% |
| 2008 Q2 | -146 Thousand USD | 71.15% |
| 2008 Q3 | 1.08 Million USD | 840.41% |
| 2007 Q1 | 210 Thousand USD | 0.0% |
| 2007 Q4 | 39 Thousand USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | -100.0% |
| 2007 FY | 39 Thousand USD | 0.0% |
| 2006 Q2 | -170 Thousand USD | 9.57% |
| 2006 Q3 | -640 Thousand USD | -276.47% |
| 2006 Q4 | - USD | 100.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q1 | -188 Thousand USD | 0.0% |
| 2005 Q2 | - USD | -100.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | 15 Thousand USD | 0.0% |
| 2004 Q4 | - USD | 100.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q2 | -560 Thousand USD | 27.18% |
| 2004 Q3 | -399 Thousand USD | 28.75% |
| 2004 Q1 | -769 Thousand USD | 0.0% |
| 2003 Q2 | - USD | -100.0% |
| 2003 Q1 | 13 Thousand USD | 116.67% |
| 2003 Q3 | - USD | 0.0% |
| 2003 FY | 13 Thousand USD | -97.69% |
| 2003 Q4 | - USD | 0.0% |
| 2002 Q1 | 333 Thousand USD | 0.0% |
| 2002 Q2 | 222 Thousand USD | -33.33% |
| 2002 FY | 562 Thousand USD | -57.84% |
| 2002 Q3 | - USD | -100.0% |
| 2002 Q4 | 6000.00 USD | 0.0% |
| 2001 Q3 | 333 Thousand USD | -0.3% |
| 2001 Q4 | 333 Thousand USD | 0.0% |
| 2001 FY | 1.33 Million USD | 15.41% |
| 2001 Q1 | 333 Thousand USD | 61.65% |
| 2001 Q2 | 334 Thousand USD | 0.3% |
| 2000 FY | 1.15 Million USD | -26.67% |
| 2000 Q1 | 384 Thousand USD | -43.11% |
| 2000 Q4 | 206 Thousand USD | 16.38% |
| 2000 Q2 | 388 Thousand USD | 1.04% |
| 2000 Q3 | 177 Thousand USD | -54.38% |
| 1999 Q3 | 400 Thousand USD | 0.0% |
| 1999 FY | 1.57 Million USD | 21.15% |
| 1999 Q4 | 675 Thousand USD | 68.75% |
| 1999 Q2 | 400 Thousand USD | 100.0% |
| 1999 Q1 | 200 Thousand USD | 0.0% |
| 1998 Q4 | 200 Thousand USD | 0.0% |
| 1998 FY | 1.3 Million USD | 550.0% |
| 1998 Q1 | 100 Thousand USD | 0.0% |
| 1998 Q2 | 800 Thousand USD | 700.0% |
| 1998 Q3 | 200 Thousand USD | -75.0% |
| 1997 FY | 200 Thousand USD | 0.0% |
| 1997 Q1 | 100 Thousand USD | 0.0% |
| 1997 Q2 | 200 Thousand USD | 100.0% |
| 1997 Q3 | 100 Thousand USD | -50.0% |
| 1997 Q4 | - USD | -100.0% |
| 1996 FY | 200 Thousand USD | 150.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1996 Q2 | 100 Thousand USD | 0.0% |
| 1996 Q3 | 200 Thousand USD | 100.0% |
| 1996 Q4 | - USD | -100.0% |
| 1995 FY | -400 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | -14262.393% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -105240.066% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 473.318% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -1736.867% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 101738.019% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -2050.379% |
| Imunon, Inc. | -720 Thousand USD | 44283.999% |
| Dynavax Technologies Corporation | 182.11 Million USD | -74.683% |
| Editas Medicine, Inc. | -99.52 Million USD | 419.636% |
| FibroGen, Inc. | 128.9 Million USD | -146.794% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 3425.601% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 105092.409% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 82.78% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 70.894% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 39.259% |
| Verastem, Inc. | -62 Thousand USD | 513208.065% |
| Zoetis Inc. | 5.83 Billion USD | 94.547% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 96.304% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 801.88% |
| Homology Medicines, Inc. | -7.22 Million USD | 4500.705% |
| Nektar Therapeutics | 53.47 Million USD | -494.875% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 109047.603% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 1714.94% |
| Perrigo Company plc | 1.68 Billion USD | 81.068% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -335.391% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 98.801% |
| Illumina, Inc. | 2.74 Billion USD | 88.406% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 97.91% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 93.928% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -3067.965% |
| Waters Corporation | 1.76 Billion USD | 81.937% |
| Biogen Inc. | 7.3 Billion USD | 95.643% |
| Evolus, Inc. | 140.52 Million USD | -126.383% |
| Adicet Bio, Inc. | -6.09 Million USD | 5316.907% |
| bluebird bio, Inc. | -4.03 Million USD | 7993.97% |
| Geron Corporation | -123.5 Million USD | 357.586% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 79.041% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 12.127% |
| Myriad Genetics, Inc. | 476.4 Million USD | 33.223% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 179.772% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 85.334% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 1120.696% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 83.295% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 97.185% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 90.819% |
| Exelixis, Inc. | 1.75 Billion USD | 81.901% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 33.152% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -30.095% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 59.137% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 50.05% |
| Blueprint Medicines Corporation | 236.58 Million USD | -34.467% |
| Insmed Incorporated | 239.63 Million USD | -32.755% |
| TG Therapeutics, Inc. | 219.1 Million USD | -45.192% |
| Incyte Corporation | 3.44 Billion USD | 90.754% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 7.494% |